Cleveland Clinic has begun clinical testing of a novel vaccine designed ultimately to prevent triple-negative breast cancer (TNBC) by priming high-risk women to mount an immune response against a “retired” lactation protein expressed only in cancer cells.
This is huge!! Triple-negative breast cancer (TNBC) accounts for about 10-15% of all #breastcancers. The term triple-negative breast cancer refers to the fact that the cancer cells don’t have #estrogen or #progesterone receptors (ER or PR) and also don’t make any or too much of the protein called #HER2. (The cells test "negative" on all 3 tests.) These cancers tend to be more common in #women younger than age 40, who are #Black, or who have a #BRCA1 mutation.
#TNBC differs from other types of invasive breast cancer in that it tends to grow and spread faster, has fewer #treatment options, and tends to have a worse #prognosis (outcome).